# Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR

> **NCT06130540** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 65 (actual)

## Conditions studied

- Giant Cell Arteritis
- Polymyalgia Rheumatica

## Interventions

- **DRUG:** Secukinumab

## Key facts

- **NCT ID:** NCT06130540
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-27
- **Primary completion:** 2025-03-12
- **Final completion:** 2025-04-02
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06130540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06130540, "Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06130540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*